Since DLBCL presents as a heterogeneous disease, encompassing cases with variable CD30+ tumor and/or CD30+ bystander cells, a functional EV-dependent transport from CD30+ cells to CD30– DLBCL cells might explain the efficacy of BV in cases with CD30– tumor cells. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.